SCHEMBL21874640

SCHEMBL21874640

Nc1cc(Br)ccc1CN[C@@H]1CCN(C(=O)O)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.40
GRM3 Q14832 2/20 0.40
BCHE P06276 4/20 0.39
ACHE P22303 4/20 0.39
BACE1 P56817 4/20 0.39
TEAD1 P28347 2/20 0.38
CCR2 P41597 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
HTT P42858 1/20 0.36
USP30 Q70CQ3 1/20 0.36
DRD4 P21917 1/20 0.36
LMNA P02545 1/20 0.36
GBA1 P04062 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CNR1 P21554 1/20 0.36
TBXA2R P21731 1/20 0.36
HRH2 P25021 1/20 0.36
SLC6A4 P31645 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21874641 1.00 GRM2 (0.40) GRM2GRM3BCHEACHEBACE1
SCHEMBL28566888 0.84 USP30 (0.55) HTTUSP30
SCHEMBL28566889 0.84 USP30 (0.55) HTTUSP30
SCHEMBL18919693 0.83 BCHE (0.46) BCHEACHEBACE1TEAD1DRD4
SCHEMBL18919696 0.83 BCHE (0.46) BCHEACHEBACE1TEAD1DRD4
SCHEMBL18919655 0.82 KDM4E (0.45) GRM2GRM3BCHEACHEBACE1
SCHEMBL18919654 0.82 KDM4E (0.45) GRM2GRM3BCHEACHEBACE1
SCHEMBL20045986 0.76 USP30 (0.48) AAK1USP30
SCHEMBL4477584 0.76 BCHE (0.58) GRM2GRM3BCHEACHEBACE1
SCHEMBL2099309 0.75 ACHE (0.47) BCHEACHEBACE1DRD4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091488-B2 1-cyano-pyrrolidine derivatives as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-08-17 US disclosed
US-20200262838-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2020-08-20 US disclosed
EP-3383859-B1 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2020-04-29 EP disclosed
CN-108290861-A 1- cyano-pyrolidin derivatives as USP30 inhibitor 特殊治疗有限公司 2018-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091488-B2 1-cyano-pyrrolidine derivatives as inhibitors of USP30 USP30, USP1, USP20 GRM2 4350/4885GRM3 4024/4885BCHE 2082/4885
US-20200262838-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 USP30, USP1, USP20 GRM2 4350/4885GRM3 4024/4885BCHE 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.